NHS England has announced that a highly targeted form of radiotherapy will be made available to thousands of men with early-stage prostate cancer, marking the first time the treatment has been offered as a standard option on the health service. The technique, known as stereotactic ablative radiotherapy (SABR), delivers concentrated doses of radiation to a tumour from multiple directions simultaneously, reducing exposure to the surrounding healthy tissue.

Conventional external beam radiotherapy for prostate cancer typically requires at least twenty treatment sessions. SABR completes the course in five, delivered across a fortnight. The clinical case for the approach is well established: the precision of the multi-beam delivery reduces the likelihood of damage to nearby organs while maintaining effectiveness against the tumour. Trials that informed the rollout were led by researchers in the UK.

Around 17,500 men are diagnosed with low or intermediate risk localised prostate cancer in England each year and would be eligible to be offered SABR. NHS modelling suggests approximately 3,500 of them may opt for it. The treatment will be made available across all 48 radiotherapy providers in England, with the first centres beginning to offer it from next week.

The reduction in treatment sessions carries consequences beyond the clinical. For patients, fewer visits means less time away from work and from family. Travel to and from hospital for cancer treatment is a significant and often underestimated burden, particularly for men who live some distance from a radiotherapy centre or who are managing the treatment alongside employment. For the NHS, the projected effect on capacity is substantial. The service estimates the rollout will free up around 50,000 appointments annually, which it expects to contribute to efforts to reduce waiting times across cancer services.

Sir Jim Mackey, NHS chief executive, said the approach would help the service provide "far more powerful and convenient care to stop their cancer spreading." Professor Peter Johnson, NHS national clinical director for cancer, described the technology as allowing clinicians to "focus a powerful and precise beam of radiotherapy directly onto the cancer, limiting the damage to healthy cells." He added that the reduction of fifteen doses would help patients return to their lives more quickly. James Murray, the Health Secretary, said the treatment would allow many patients to complete their course "in a fraction of the time compared with conventional radiotherapy," and linked the announcement to the government's £70 million investment in new linear accelerator machines.

That investment is central to making the rollout viable. The machines required to deliver SABR are more technically advanced than those used for standard radiotherapy, and expanding access has required significant capital spending to equip centres across England. The government has framed this as part of a wider National Cancer Plan aimed at expanding access to newer treatments.

SABR is not appropriate for every man with localised prostate cancer. Eligibility depends on individual clinical factors, and specialists have been clear that patients should discuss their specific circumstances with their treating team before drawing conclusions about which option is right for them. The treatment has been through clinical trials but, as with any intervention, it carries its own risk profile that must be weighed against the alternatives.

Prostate cancer is the most common cancer diagnosed in men in the UK, with more than 55,000 new cases recorded each year and roughly 12,300 deaths annually. The scale of the disease makes even incremental improvements in treatment delivery significant at a population level. The NHS reported in early 2026 that around four in five patients were receiving a diagnosis or all-clear within four weeks, and that nearly 92 per cent of patients began cancer treatment within a month during 2025/26. The addition of SABR to the standard offer sits within that broader pattern of attempting to speed up and sharpen the quality of cancer care across England.

‍